Immix Biopharma, Inc. (IMMX) Cash Flow Statement
Immix Biopharma, Inc. (IMMX) generated -$38.5M of operating cash flow over the twelve months to 2026-06-30, spent $591111 on capital expenditure and had free cash flow of -$39.1M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IMMXImmix Biopharma, Inc.Follow IMMX — free
—
Price chart with a free account
- Market cap
- 583.0M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -1.6 | -7.4 | -11.4 | -14.6 | -23.9 | -38.5 | |
| Capital expenditure | 0.0 | — | 0.1 | 1.2 | 0.7 | -0.6 | |
| Free cash flow | -1.6 | — | -11.4 | -15.8 | -24.7 | -39.1 | |
| Share repurchases | — | 0.1 | — | — | — | — | |
| Stock-based compensation | 0.2 | 0.6 | 2.6 | 3.0 | 2.4 | — |
USD millions · SEC XBRL
Immix Biopharma, Inc. — questions
- What is Immix Biopharma, Inc.'s operating cash flow?
- -$38.5M over the twelve months to 2026-06-30.
- How much does Immix Biopharma, Inc. spend on capital expenditure?
- $591111 over the twelve months to 2026-06-30.
- What is Immix Biopharma, Inc.'s free cash flow?
- -$39.1M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Immix Biopharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.